SMT201500157B - Pirazolilaminopiridine come inibitori di fak - Google Patents

Pirazolilaminopiridine come inibitori di fak

Info

Publication number
SMT201500157B
SMT201500157B SM201500157T SM201500157T SMT201500157B SM T201500157 B SMT201500157 B SM T201500157B SM 201500157 T SM201500157 T SM 201500157T SM 201500157 T SM201500157 T SM 201500157T SM T201500157 B SMT201500157 B SM T201500157B
Authority
SM
San Marino
Prior art keywords
pyrazolylaminopyridines
fak inhibitors
fak
inhibitors
Prior art date
Application number
SM201500157T
Other languages
English (en)
Italian (it)
Inventor
Thomas Faitg
Neil W Johnson
Hong Lin
Jiri Kasparec
Mark Mellinger
Ren Xie
Xin Peng
Jerry Leroy Adams
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42132177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201500157(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of SMT201500157B publication Critical patent/SMT201500157B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SM201500157T 2008-10-27 2015-07-03 Pirazolilaminopiridine come inibitori di fak SMT201500157B (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10856808P 2008-10-27 2008-10-27
US17851709P 2009-05-15 2009-05-15
US24243209P 2009-09-15 2009-09-15
PCT/US2009/062163 WO2010062578A1 (fr) 2008-10-27 2009-10-27 Pyrazolylaminopyridines au titre d'inhibiteurs de fak

Publications (1)

Publication Number Publication Date
SMT201500157B true SMT201500157B (it) 2015-09-07

Family

ID=42132177

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500157T SMT201500157B (it) 2008-10-27 2015-07-03 Pirazolilaminopiridine come inibitori di fak

Country Status (36)

Country Link
US (6) US20100113475A1 (fr)
EP (1) EP2421537B1 (fr)
JP (1) JP5642689B2 (fr)
KR (1) KR101512217B1 (fr)
CN (1) CN102264371B (fr)
AR (1) AR073993A1 (fr)
AU (1) AU2009320144B2 (fr)
BR (1) BRPI0920053B8 (fr)
CA (1) CA2741760C (fr)
CL (1) CL2011000933A1 (fr)
CO (1) CO6361929A2 (fr)
CR (1) CR20110264A (fr)
CY (1) CY1116399T1 (fr)
DK (1) DK2421537T3 (fr)
DO (1) DOP2011000113A (fr)
EA (1) EA021927B1 (fr)
ES (1) ES2539835T3 (fr)
HK (1) HK1161680A1 (fr)
HR (1) HRP20150531T1 (fr)
IL (1) IL212444A (fr)
JO (1) JO3067B1 (fr)
MA (1) MA32727B1 (fr)
MX (1) MX2011004369A (fr)
MY (1) MY161890A (fr)
NZ (1) NZ592477A (fr)
PE (1) PE20110941A1 (fr)
PL (1) PL2421537T3 (fr)
PT (1) PT2421537E (fr)
RS (1) RS54045B1 (fr)
SG (1) SG195608A1 (fr)
SI (1) SI2421537T1 (fr)
SM (1) SMT201500157B (fr)
TW (1) TWI454467B (fr)
UY (1) UY32200A (fr)
WO (1) WO2010062578A1 (fr)
ZA (1) ZA201102892B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
MX2013008654A (es) * 2011-01-26 2013-09-02 Glaxosmithkline Intellectual Property Ltd Combinaciones.
AU2012216893B2 (en) 2011-02-17 2016-08-11 Cancer Therapeutics Crc Pty Limited FAK inhibitors
CA2827172C (fr) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Inhibiteurs selectifs de fak
US9192604B2 (en) 2011-06-28 2015-11-24 Glaxosmithkline Intellectual Property (No. 2) Limited Method of administration and treatment
US10106834B2 (en) 2013-10-09 2018-10-23 The General Hospital Corporation Methods of diagnosing and treating B cell acute lymphoblastic leukemia
US10532056B2 (en) 2015-06-29 2020-01-14 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
CN108948019B (zh) * 2017-05-18 2022-07-08 广东东阳光药业有限公司 黏着斑激酶抑制剂及其用途
WO2019117813A1 (fr) * 2017-12-15 2019-06-20 National University Of Singapore Agents thérapeutiques ciblant une kinase d'adhésion focale pour le traitement du glaucome et de la fibrose
BR112020018585A8 (pt) 2018-03-12 2022-12-06 Inst Nat Sante Rech Med Uso de mimeticos de restrição calórica para potencializar a quimioimunoterapia para o tratamento de câncer
CN108912095B (zh) * 2018-08-09 2019-08-20 广州安岩仁医药科技有限公司 苯并咪唑类化合物及其制备方法和应用
EP3856190A4 (fr) * 2018-09-27 2022-09-21 Dana Farber Cancer Institute, Inc. Dégradation de fak ou fak et alk par conjugaison d'inhibiteurs de fak et d'alk avec des ligands de ligase e3 et procédés d'utilisation
CN113387947B (zh) * 2021-07-12 2022-07-01 中国科学院成都生物研究所 调节雌激素受体合成活性的吡唑并吡啶衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US166139A (en) * 1875-07-27 Improvement in dental pluggers
WO2000014105A1 (fr) * 1998-09-08 2000-03-16 Agouron Pharmaceuticals, Inc. Modification de la proteine recepteur 2 de vegf et ses methodes d'utilisation
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
EP2287156B1 (fr) * 2003-08-15 2013-05-29 Novartis AG Composés de 2,4-di(phenylamino)pyrimidine er leur utilisation dans le traitement de maladies néoplastiques, inflammatoires et du système immunitaire
GB0419160D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EP1746096A1 (fr) * 2005-07-15 2007-01-24 4Sc Ag Analogues de 2-arylbenzothiazole utiles comme agents anticancereux
PL2134689T3 (pl) * 2007-03-16 2014-10-31 Scripps Research Inst Inhibitory kinazy ognisk adhezyjnych
JP2011512413A (ja) * 2008-02-19 2011-04-21 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｆａｋの阻害剤としてのアニリノピリジン
CA2726508C (fr) * 2008-06-17 2016-06-07 Astrazeneca Ab Composes pyridines

Also Published As

Publication number Publication date
US20100113475A1 (en) 2010-05-06
AU2009320144B2 (en) 2013-11-21
MA32727B1 (fr) 2011-10-02
CN102264371B (zh) 2013-10-02
AR073993A1 (es) 2010-12-15
EP2421537A1 (fr) 2012-02-29
HRP20150531T1 (hr) 2015-06-19
JP5642689B2 (ja) 2014-12-17
US20140107131A1 (en) 2014-04-17
TW201028394A (en) 2010-08-01
PE20110941A1 (es) 2012-02-08
MY161890A (en) 2017-05-15
IL212444A (en) 2015-11-30
UY32200A (es) 2010-05-31
AU2009320144A1 (en) 2010-06-03
KR20110080172A (ko) 2011-07-12
US9446034B2 (en) 2016-09-20
US20150265589A1 (en) 2015-09-24
MX2011004369A (es) 2011-05-25
CN102264371A (zh) 2011-11-30
SG195608A1 (en) 2013-12-30
CO6361929A2 (es) 2012-01-20
BRPI0920053B8 (pt) 2021-05-25
TWI454467B (zh) 2014-10-01
IL212444A0 (en) 2011-06-30
EA201170617A1 (ru) 2011-12-30
HK1161680A1 (en) 2012-08-03
DOP2011000113A (es) 2011-07-15
DK2421537T3 (da) 2015-06-22
PT2421537E (pt) 2015-07-03
RS54045B1 (en) 2015-10-30
WO2010062578A1 (fr) 2010-06-03
EP2421537B1 (fr) 2015-04-08
ES2539835T3 (es) 2015-07-06
JO3067B1 (ar) 2017-03-15
KR101512217B1 (ko) 2015-04-15
CA2741760C (fr) 2016-02-23
EA021927B1 (ru) 2015-09-30
BRPI0920053B1 (pt) 2019-11-26
EP2421537A4 (fr) 2012-06-13
BRPI0920053A2 (pt) 2015-12-15
US20160095841A1 (en) 2016-04-07
US20110207743A1 (en) 2011-08-25
SI2421537T1 (sl) 2015-06-30
CA2741760A1 (fr) 2010-06-03
NZ592477A (en) 2013-01-25
JP2012506876A (ja) 2012-03-22
US9012479B2 (en) 2015-04-21
CY1116399T1 (el) 2017-02-08
CL2011000933A1 (es) 2011-10-21
ZA201102892B (en) 2012-02-29
PL2421537T3 (pl) 2015-08-31
CR20110264A (es) 2011-10-04
US20110269774A1 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
CY2020023I1 (el) Αναστολεiς βητα-λακταμασων
CY2017042I1 (el) Ενωσεις πυρρολοπυριμιδινης ως αναστολεις cdk
CY2017016I1 (el) Αναστολεις πρωτεασωματος
SMT201500157B (it) Pirazolilaminopiridine come inibitori di fak
SMT201600008B (it) Composti di piridazinone
SMT201600311B (it) Inibitori di cdk
SMT201500043B (it) Indazoli ossazolo-sostituiti come inibitori di pi13-chinasi
SMT201600104B (it) Inibitore di bromodominio benzodiazepinico
SMT201600081B (it) Inibitore di bromodominio di benzodiazepina
SMT201500271B (it) Inibitori di neprilisina
DK2421825T3 (da) Azetidinyldiamider som monoacylglycerollipase-inhibitorer
BRPI0907376A8 (pt) fotobiorreator
DK2288375T3 (da) Pegylerede insulin-lispro-forbindelser
DK2634232T3 (da) Sammensætninger
BRPI0920707A2 (pt) compostos
DK2242759T3 (da) Forbindelser
BRPI0918564A2 (pt) inibidores
DK2323972T3 (da) C7-fluor-substituerede tetracylinforbindelser
DK2297162T3 (da) Forbindelser
DK2300238T3 (da) Skyggebillede-sikkerhedstræk
BRPI0916432A2 (pt) compostos
BRPI0912152A2 (pt) umbilical
BRPI0923592A2 (pt) composto
DK2240506T3 (da) IAP inhibitorer
DK2206698T3 (da) Ethynylindolforbindelser